Octapharma issues recall of one lot of its immune globulin Octagam

Octapharma
Octagam voluntary recall.

Switzerland’s Octapharma AG has issued an urgent, voluntary recall of one lot of its Octagam immune globulin used intravenously after several reports of allergic type skin reactions.

The lot Octagam Immune Globulin Intravenous (Human) 5% being recalled is K551A8441 and was manufactured at the company’s facility in Vienna, Austria. The plant received FDA approval to produce the drug a little over a year ago.

No other lots of Octagam are affected by the recall, the company said in a posting on the FDA website.

Octagam is used to treat primary humoral immunodeficiencies, such as congenital agammaglobulinemia, common variable immunodeficiency, Wiskott-Aldrich syndrome and other severe combined immunodeficiencies.

No serious injuries from the products have been reported.

In October, Octapharma shelled out about $91 million to gain exclusive global license to certain intellectual property behind Glycotope’s recombinant technology as well as a minority stake in the German biotech.

-see the FDA posting

Related Article:
Octapharma buys into Glycotope with an €80M cash deal

Read more on

Suggested Articles

Already developing coronavirus treatments, Takeda struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan

Pfizer struck a deal to produce Gilead Sciences' remdesivir, which has been running short at some hard-hit U.S. hospitals.

On the heels of last week's deal for 120 million Pfizer-BioNTech shots, Japan has locked down 120 million more vaccines from AstraZeneca.